Malignant Peripheral Nerve Sheath Tumor clinical trials
17 active trials name this condition. Describe your situation to see which ones look like a fit.
Refine by biomarker
By location
- A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
- Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor
- A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]
- Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
- A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
- A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
- NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
- B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
- Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
- SPEARHEAD-3 Pediatric Study
- Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins
- Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
- Neurofibromatosis Type 1 Tumor Early Detection Study
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Malignant Peripheral Nerve Sheath Tumor” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.